Methods of using IL-31 to treat chronic obstructive pulmonary disease (COPD)
AssigneeZymoGenetics, Inc.
InventorsJanine M. Bilsborough, Eric M. Chadwick, Sherri L. Mudri
Life of this patent
Estimating the term…
Abstract
Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proinflammatory cytokines and include administration of the IL-31 agonist during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state.
Claims7
A method of inhibiting, minimizing, reducing, or neutralizing chronic obstructive pulmonary disease (COPD) in a mammal, comprising administering an Interleukin-31 (IL-31) agonist to the mammal wherein pulmonary inflammation is reduced and wherein the IL-31 agonist is administered during sensitization or challenge and wherein the IL-31 agonist comprises amino acid residues 27 to 164 of SEQ ID NO:
- 2.
A method of inhibiting, minimizing, reducing, or neutralizing chronic obstructive pulmonary disease (COPD) in a mammal, comprising administering an Interleukin-31 (IL-31) agonist to the mammal wherein pulmonary inflammation is reduced and wherein the IL-31 agonist is administered during sensitization or challenge and wherein the IL-31 agonist has at least 95% sequence identity to the polypeptide comprising the amino acid sequence of SEQ ID NO:2 from residue 27 to 164.
Dependencies are inferred from the claim text.